









Markets
/
Stocks
/
nasdaq-lctx
/

Lineage Cell Therapeutics Inc

LCTX

1.470USD

-0.020-1.34%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

72.08MMarket Cap

LossP/E TTM



Lineage Cell Therapeutics Inc

1.470

-0.020-1.34%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lineage Cell Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Lineage Cell Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 123 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.80.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lineage Cell Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

123 / 391

Overall Ranking

242 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Lineage Cell Therapeutics Inc Highlights

StrengthsRisks

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 62.73% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.56M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 14.56M.

Overvalued

The company’s latest PE is -5.40, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 95.36M shares, decreasing 22.47% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 2.40M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.05.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

4.800

Target Price

+213.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Lineage Cell Therapeutics Inc is 6.63, ranking 224 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 6.61M, representing a year-over-year increase of 130.40%, while its net profit experienced a year-over-year increase of 126.00%.

Score

Industry at a Glance

Previous score

6.63

Change



Financials

6.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.49

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.80

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.47

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lineage Cell Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Lineage Cell Therapeutics Inc is 6.55, ranking 252 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.40, which is -15.91% below the recent high of -4.54 and -165.06% above the recent low of -14.30.

Score

Industry at a Glance

Previous score

6.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 123/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Lineage Cell Therapeutics Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 3.00, with a high of 9.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

4.800

Target Price

+222.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Lineage Cell Therapeutics Inc

LCTX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Lineage Cell Therapeutics Inc is 6.76, ranking 139 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.84 and the support level at 1.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.90

Change

-0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.028

Sell

RSI(14)

38.012

Neutral

STOCH(KDJ)(9,3,3)

29.349

Neutral

ATR(14)

0.099

Low Volatility

CCI(14)

-86.409

Neutral

Williams %R

88.095

Oversold

TRIX(12,20)

-0.763

Sell

StochRSI(14)

20.124

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.504

Sell

MA10

1.507

Sell

MA20

1.633

Sell

MA50

1.683

Sell

MA100

1.705

Sell

MA200

1.494

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Lineage Cell Therapeutics Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 41.40%, representing a quarter-over-quarter decrease of 2.12%. The largest institutional shareholder is The Vanguard, holding a total of 9.64M shares, representing 3.87% of shares outstanding, with 0.87% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Broadwood Capital, Inc.

49.56M

Chernett (Jorey)

11.45M

The Vanguard Group, Inc.

Star Investors

9.01M

+6.18%

Defender Capital LLC

6.81M

+0.32%

Raffles Capital Management, LLC

5.39M

-0.08%

Comerica, Inc.

4.60M

BlackRock Institutional Trust Company, N.A.

2.23M

-1.33%

Geode Capital Management, L.L.C.

2.42M

-0.49%

Renaissance Technologies LLC

Star Investors

1.91M

-3.38%

Millennium Management LLC

2.68M

+3.05%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lineage Cell Therapeutics Inc is 3.81, ranking 117 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.81. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Lineage Cell Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.